###### Key messages

What is already known about this subject?
=========================================

-   Health-related quality of life (HRQoL) impairment in patients with psoriatic arthritis (PsA) can be significant, similar in extent to patients with rheumatoid arthritis. The presence of plaque psoriasis, in addition to arthritis, is thought to be a significant contributor to overall morbidity in patients with PsA.

-   While current therapies can have varying success in treating the differing manifestations of PsA, it is currently unclear to what degree treating joint and/or skin symptoms in PsA correlates with improvements in patients' HRQoL.

What does this study add?
=========================

-   Leveraging data from clinical trials in PsA, improvements in joint symptoms were pivotal in improving overall patient HRQoL. However, improvements in both joint and skin manifestations were necessary to achieve optimal patient HRQoL improvements in both physical and mental domains.

How might this impact on clinical practice or future developments?
==================================================================

-   The results of this study indicate that treatment regimens that effectively treat patient joint and skin symptoms should be considered to achieve optimal improvements in overall HRQoL.

Introduction {#s1}
============

Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease involving articular and extra-articular symptoms, particularly psoriasis (PsO).[@R1] Of note, health-related quality of life (HRQoL) impairment in PsA is similar to rheumatoid arthritis (RA), even though patients with PsA may have, on average, fewer joints involved as compared with those with RA, and may relate to the additional burden of skin PsO and other domains of disease.[@R2] While current disease-modifying antirheumatic drugs (DMARDs) can have varying success in treating the differing manifestations of PsA, it is currently unclear to what degree treating joint and/or skin symptoms in PsA correlates with improvements in patients' HRQoL. In this post hoc analysis, we leveraged clinical trial data from SPIRIT-P1 and SPIRIT-P2,[@R8] which investigated the interleukin-17A antagonist ixekizumab for the treatment of PsA, to assess the contributions of joint and skin symptom improvements on patients' HRQoL.

Methods {#s2}
=======

Study design and patient population {#s2-1}
-----------------------------------

Data within this integrated post hoc analysis were derived from SPIRIT-P1 (NCT01695239) and SPIRIT-P2 (NCT02349295). The study design and patient populations for each study have been described previously.[@R8] Briefly, the SPIRIT studies are phase 3 double-blind, placebo-controlled clinical trials involving patients with active PsA. In SPIRIT-P1, the patient population was biologic DMARD-naive. In SPIRIT-P2, patients must have had an inadequate response or intolerance to TNF inhibitors. In both trials, enrolled patients had ≥3 of 68 tender joint and ≥3 of 66 swollen joint counts and had an active or documented history of PsO at study entry.

Patients were randomised to placebo (until week 24) or ixekizumab 80 mg once every 4 or 2 weeks. At week 16, patients deemed inadequate responders were required to add/modify medications. In these analyses, patients were included regardless of the treatment group.

Outcomes {#s2-2}
--------

Improvements in joint and skin symptoms were measured as per cent improvement from baseline by Disease Activity Index for Psoriatic Arthritis (DAPSA) and Psoriasis Area and Severity Index (PASI) scores, respectively.[@R10] DAPSA is a composite measure incorporating swollen and tender joints, function, pain and disease activity, but does not directly measure PsO skin symptoms.[@R11] Improvements in HRQoL were measured as change from baseline (CFB) by the following instruments: European Quality of Life-Five Dimensions (EQ-5D) Visual Analogue Score (VAS), activity impairment domain of the Work Productivity and Activity Impairment (WPAI) Questionnaire[@R12] and 36-Item Short-Form Health Survey (SF-36).[@R13]

Statistical analyses {#s2-3}
--------------------

Post hoc analyses were conducted on all ixekizumab-treated and placebo-treated patients with a baseline PsO of ≥3% or ≥10% body surface area (BSA) from the integrated data set. Missing data were imputed with the last observation carried forward. For patients classified as inadequate responders at week 16, data for week 24 were imputed from the week 16 time point.

The combined effects of joint and skin improvements on HRQoL were modelled using the smoothing spline method (both as CFB).[@R14] HRQoL was assumed to be a smooth function of joint and skin symptoms without imposing specific functional form. The smooth function was expressed as a linear combination of a collection of basis functions. The degree of smoothness was controlled by an additional parameter to avoid overfitting. The unknown parameters involving the basis function can be solved efficiently using ridge regression techniques, whereas the smoothing parameter is selected using restricted marginal likelihood. This analysis was conducted using R V.3.3.3 with the general smoothing splines (gss) package (V.2.1--7 or later).

Results {#s2-4}
-------

We investigated the relationship between improvements in joint and skin symptoms at week 24 on patients' HRQoL using integrated results from the SPIRIT trials for 402 patients with active PsA and BSA ≥3% (including 224 patients with BSA ≥10%) at baseline ([table 1](#T1){ref-type="table"}). Joint involvement was similar in the BSA ≥3% and BSA ≥10% groups. Smoothing spline modelling was performed and a colour spectrum was applied to HRQoL improvements ([figure 1A,B](#F1){ref-type="fig"}).

###### 

Baseline characteristics of patients with baseline ≥3% BSA and ≥10% BSA

                                                    SPIRIT Trial Integrated Database   
  ------------------------------------------------- ---------------------------------- -------------
  Age, years                                        49.8 (11.6)                        49.1 (11.7)
  Male                                              206 (51.2%)                        131 (58.5%)
  Weight, kg                                        87.8 (21.4)                        88.4 (21.8)
  BMI, kg/m^2^                                      30.5 (7.4)                         30.2 (7.4)
  Race                                                                                 
   White                                            369 (92.0%)                        199 (89.2%)
   Asian                                            22 (5.5%)                          18 (8.1%)
   Other                                            10 (2.4%)                          6 (2.7%)
  Time since psoriatic arthritis diagnosis, years   8.6 (7.9)                          8.7 (7.6)
  Time since psoriasis diagnosis, years             16.9 (12.6)                        17.5 (12.4)
  cDMARD current use                                226 (56.2%)                        122 (54.5%)
   Methotrexate current use                         188 (46.8%)                        104 (46.4%)
  Prior TNFi experience                             203 (50.5%)                        106 (47.3%)
  Baseline disease scores                                                              
   Tender joint count, 68 joints                    22.1 (15.0)                        22.3 (14.9)
   Swollen joint count, 66 joints                   11.9 (8.6)                         11.8 (8.0)
   CRP, mg/L                                        16.7 (27.2)                        17.5 (27.6)
   DAPSA score                                      48.7 (22.6)                        49.0 (22.0)
   % BSA of psoriasis ‡                             18.3 (18.5)                        28.7 (19.1)
   PASI total score                                 8.5 (8.3)                          12.0 (9.3)
  Baseline quality of life scores                                                      
   DLQI total score                                 8.7 (6.9)                          9.8 (7.2)
   EQ-5D VAS score                                  52.5 (21.0)                        51.5 (20.9)
   SF-36 domain scores                                                                 
    Bodily pain                                     37.9 (19.7)                        38.5 (20.4)
    General health                                  44.6 (19.3)                        44.5 (19.4)
    Mental health                                   64.4 (21.8)                        64.2 (21.6)
    Physical functioning                            41.8 (26.2)                        42.6 (26.2)
    Role emotional                                  71.7 (27.0)                        72.7 (26.8)
    Role physical                                   43.9 (25.0)                        44.1 (25.4)
    Social functioning                              63.3 (27.4)                        64.7 (27.7)
    Vitality                                        40.6 (21.8)                        41.7 (21.1)
   WPAI---activity impairment                       53.0 (25.3)                        50.7 (24.9)

Data presented are mean (SD) or n (%).

\*Placebo: n=134, ixekizumab: n=268.

†Placebo: n=68, ixekizumab: n=156.

‡BSA severity ratings: \<3%=mild, 3%--10%=moderate, \>10%=severe.

BMI, body mass index; BSA, body surface area; cDMARD, conventional disease-modifying antirheumatic drug; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; EQ-5D, European Quality of Life-Five Dimensions; PASI, Psoriasis Area and Severity Index; SF-36, 36-Item Short-Form Health Survey; TNFi, TNF inhibitor; VAS, Visual Analogue Score; WPAI, Work Productivity and Activity Impairment.

![Response surface modelling. (A) Three-dimensional scatterplot and (B) response surface of scatterplot estimated by smoothing spline method of skin (y-axis, PASI---percent improvement), joint (x-axis, DAPSA---percent improvement) and HRQoL (z-axis, EQ-5D---change from baseline) improvement at week 24. A colour spectrum is applied to health-related quality of life (blue (least improvement) to red (greatest improvement)). DAPSA, Disease Activity Index for Psoriatic Arthritis; EQ-5D, European Quality of Life-Five Dimensions; PASI, Psoriasis Area and Severity Index; VAS, Visual Analogue Score.](annrheumdis-2018-215003f01){#F1}

In models with EQ-5D VAS, HRQoL improvements were highest (33.1 CFB) when patients achieved 100% improvement in both DAPSA and PASI scores ([figure 2](#F2){ref-type="fig"}). Joint symptom improvement alone (ie, 100%/0% DAPSA/PASI improvements) yielded a 17.7 CFB improvement. while skin symptom clearance alone (ie, 0%/100% DAPSA/PASI improvements) yielded a −1.2 CFB improvement. In patients with ≥10% BSA, a greater dependence on skin symptom improvement was necessary to achieve optimal EQ-5D VAS scores ([figure 2](#F2){ref-type="fig"}). Similar results were observed in models with the activity impairment domain of WPAI ([online supplementary figure S1](#SP1){ref-type="supplementary-material"}). When the models were adjusted for age, gender and biologic experience as covariates, similar results were also observed (data not shown).
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![Impact of joint and skin improvements on patient health-related quality of life as measured by EQ-5D VAS. Heat maps depict change from baseline in EQ-5D VAS at week 24, with a range from least improvement (blue) to greatest improvement (red). Joint and skin improvements measured by per cent improvements from baseline DAPSA and PASI scores at week 24, respectively. Patients with baseline psoriasis of ≥3% (A) and ≥10% BSA (B) are depicted in the left and right panels, respectively. BSA, body surface area; DAPSA, Disease Activity Index for Psoriatic Arthritis; EQ-5D, European Quality of Life-Five Dimensions; PASI, Psoriasis Area and Severity Index; VAS, Visual Analogue Score.](annrheumdis-2018-215003f02){#F2}

In models incorporating all SF-36 domains, improvement in joint symptoms alone yielded achievement of minimally clinically important difference (MCID) (≥5 improvement) in all domains in patients with ≥3% BSA; however, when skin symptom improvements were also present, less joint symptom improvement was needed to achieve MCIDs for the domains (except vitality) with general health and social functioning particularly dependent on skin symptom resolution (online supplementary [Figure S2A](#SP1){ref-type="supplementary-material"}). The greatest improvements were observed across all domains, except bodily pain, when both joint and skin symptoms improved.

In patients with ≥10% BSA, the necessity of skin symptom improvement increased for general health, social functioning, bodily pain, and vitality (online supplementary [Figure S2B](#SP1){ref-type="supplementary-material"}). In contrast, improvement in joint symptom alone was sufficient for optimal improvements in mental health and role emotional, which also exhibited the smallest CFB at week 24 in the modelling.

Discussion {#s2-5}
----------

We leveraged data from two phase 3 clinical trials to model the relative impact of joint and skin improvements on HRQoL in patients with active PsA and PsO. As measured by non-disease-specific patient-reported outcome (PRO) measures, improvements in joint symptoms were a larger driver of improvements in patient HRQoL than those for PsO. However, improvements in both joint and skin manifestations are necessary to achieve optimal patient HRQoL levels.

In the models built with patients with greater PsO involvement at baseline (≥10% BSA), skin symptom improvement was more prominent in positively affecting the scores of EQ-5D VAS, WPAI---activity impairment domain, and four of eight domains of SF-36. Importantly, the levels of tender and swollen joints and DAPSA scores were similar between patients with baseline PsO of ≥3% and BSA of ≥10%. Collectively, these data indicate that the relative contribution of skin improvement to improvements in HRQOL is dependent, to a degree, on the level of PsO at initiation of treatment.

In two domains of SF-36 (mental health and role emotional), there was less dependence on skin improvements to achieve HRQoL improvements in the models built with data from patients with baseline PsO of ≥10% BSA. Reasons for this observation are unclear as PASI responses have been previously associated with improvement in the mental aspects of HRQoL in patients with PsA.[@R15] These two particular domains exhibited the smallest overall improvements at week 24. Coupled with fewer patients with baseline PsO of ≥10% BSA, pattern estimates could have been more greatly influenced by fewer subjects within certain regions of the model.

Previous clinical trials have investigated the relative impact of improvements in joint and skin symptoms on PROs.[@R15] Collectively, the studies demonstrated that the greatest improvements in HRQoL were achieved when patients achieved clinically significant improvements in both joint and skin symptoms, particularly with respect to the mental aspects of the disease (eg, SF-36 MCS). Improvements in the physical aspects of the disease (eg, SF-36 PCS) were more strongly associated with joint symptom improvement.

The analyses presented here demonstrate that HRQoL improvements, measured by SF-36 domains, as well as the EQ-5D VAS and WPAI domains, require both joint and skin improvements for optimal responses. These analyses differ from previous disclosures, in part, by examining the correlation of a response rather than the ability of a patient to achieve a response.[@R15] With current therapies, it may be possible for patients to achieve higher clinical efficacy benchmarks than those previously considered standard (eg, PASI75 and American College of Rheumatology response criteria with 20% improvement (ACR20)). Using our methods herein, we were able to predict the impact of reaching higher efficacy thresholds on patient HRQoL. In addition, previous reports examined only patients treated with TNF inhibitors. We applied the relative efficacy improvements from both placebo-treated and ixekizumab-treated patients to our model.

To measure joint symptom improvement, we utilised DAPSA, which incorporates PROs. Considering that we employed PRO to measure patient HRQoL, this could potentially lead to some bias. Therefore, we also measured joint symptom improvement using either tender or swollen joint counts. Both of these models also suggest that improvements in both joint and skin manifestations are necessary to achieve optimal patient HRQoL levels ([online supplementary figures S3 and S4](#SP1){ref-type="supplementary-material"}).

There are limitations to our analyses. Relatively smaller numbers of patients have joint symptom improvement alone than those of patients having skin symptom improvement alone. However, the wide distribution of joint and skin improvements still allows coverage of the entire spectrum without extrapolating the result beyond what was observed. DAPSA and PASI, as measures in themselves, cannot fully capture the extent of PsA severity. DAPSA does not directly assess periarticular domains of PsA (enthesitis and dactylitis), while PASI does not necessarily account for difficult-to-treat locations of PsO (eg, genital, palms and nails). Future analyses incorporating these domains, which can influence HRQoL, would provide additional insight. Lastly, the interpretation of these analyses was limited to patients with PsA with PsO of ≥3% BSA as reliable assessment of PsO activity becomes problematic in patients with less extensive disease. It is therefore unclear to what extent these results are applicable to patients with milder PsO.

In summary, using clinical trial data, we demonstrated that improvements in both joint and skin manifestations are necessary for optimal HRQoL in patients with active PsA and PsO. Therefore, therapies targeting both joint and skin symptoms should be preferred to achieve optimal improvements in overall quality of life.
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